WEC
ARCT icon

Winslow Evans & Crocker’s Arcturus Therapeutics ARCT Stock Holding History

Winslow Evans & Crocker’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-143
Closed -$6.54K – 1297
2015
Q2 		$6.54K Buy
+143
New +$6.55K ﹤0.01% 1026

Other funds holding ARCT

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
HCM
Hayman Capital Management Dallas, Texas $63.3M AUM 3.78% 1-Year Est. Return

Winslow Evans & Crocker's ARCT Position: Q3 2015 in Review

Winslow Evans & Crocker sold out of Arcturus Therapeutics (ARCT) in Q3 2015, closing a stake of 143 shares — an estimated $6.54K sold.

Winslow Evans & Crocker first reported a position in ARCT in Q2 2015 and held it in 1 quarter. The position peaked at $6.54K in Q2 2015. 37 funds tracked by Wall St. Rank hold ARCT as of Q3 2015.

  • Winslow Evans & Crocker reported no remaining Arcturus Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Winslow Evans & Crocker sold 143 Arcturus Therapeutics shares in Q3 2015, an estimated $6.54K.
  • Winslow Evans & Crocker first reported a position in Arcturus Therapeutics in Q2 2015 and held it in 1 quarter.
  • Winslow Evans & Crocker's Arcturus Therapeutics position peaked at $6.54K in Q2 2015.
  • 37 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2015.

Based on Winslow Evans & Crocker's 13F filing for Q3 2015, filed 21 Oct 2015.